Skip to content
1 Minute Read

CRIO Welcomes Dr. Margaretta Nyilas to its Board of Directors

 BOSTON, MA – November 3, 2022CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. 

Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a proven track record of delivering high value assets such as ABILIFY MYCITE® (aripiprazole tablets with sensors), ABILIFY MAINTENA® (aripiprazole),  REXULTI™ (brexpiprazole), and ABILIFY® (aripiprazole). 

Currently, she is serving as a director and strategic advisor for the biopharmaceutical industry and as Venture Affiliate Partner with Boston Millennia Partners. 

Throughout her career, Dr. Nyilas has championed innovation in the clinical trial process and was an early adopter of electronic source data collection. She joins CRIO as its first independent director, bringing her unique blend of knowledge in clinical operations, technology and medicine.

“We couldn’t be happier with Margaretta joining the Board,” says Raymond Nomizu, JD, CEO and co-founder at CRIO. “With over 2,000 sites using our system across thousands of studies, we are leveraging our technology to create efficiencies for sites, sponsors and CROs. As an innovator in eClinical technology, Margaretta will provide invaluable insight and guidance to position our product roadmap and vision to the needs of clinical trial sponsors.”

Dr. Nyilas joins CRIO board members Sankesh Abbhi, formerly CEO of ArisGlobal; Tom Peterson, Venture Partner at Rally Ventures; and CEO, Raymond Nomizu. Ren Roome of Boston Millennia Partners serves as a board observer.

About CRIO

CRIO is an eClinical solution provider delivering innovative data capture technology for sites, sponsors and CROs. Innovation is at the heart of everything we do. As the industry’s leading eSource provider, CRIO’s unique architecture enables a single point of data capture that embeds quality and transparency at the point of entry, and creates significant downstream efficiencies. Finally. One system. One source. Today, CRIO supports more than 2,000 medical research sites and 4,000+ protocols worldwide. For more information about CRIO, visit clinicalresearch.io.

 

by Daenya McDonald Marketing Director
Share this post
You may also find interesting
Explore our Blog
Letter from the CEO
CRIO Company News
2 Minute Read -

Letter from the CEO

Since our launch in 2016, CRIO  has achieved our mission of becoming the leading site-centric eSource and CTMS technology, now reaching 2,000+ sites in 25+ countries. To prepare for CRIO’s upcoming growth phase, we conducted a meticulous fundraising process led by a healthcare specialized investment bank. Following extensive engagement with potential investors, we are thrilled...

Press Release Image
CRIO Company News
2 Minute Read -

CRIO Poised for Continued Expansion Following Significant Investment by The Riverside Company

Industry leading eSource provider plans accelerated expansion of its product roadmap to further enhance its value proposition to clinical research sites, biopharmaceutical companies and CROs. Boston, MA, May 21, 2024 – CRIO, Inc., a leading provider of eSource and other eClinical technologies, announced that it has received a significant investment from The Riverside Company, a...

JSCDM Header
CRIO Company News
1 Minute Read -

JSCDM: Comparison of electronic health records and electronic source data in clinical research trials

The Journal of the Society for Clinical Data Management (JSCDM) recently published the original research article “Comparison of electronic health records and electronic source data in clinical research trials: a retrospective review” which was co-authored by Amelia Tian, CRIO Solutions Consultant, and Olivia Dennis, CRIO Analytics and Data Migration Manager, alongside Dr. Elena Christofides (Endocrinology...

Get articles delivered to your inbox, every week